Replies to post #190705 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Great write up cabel. Superb.

[F1ash]

#4 is not correct because I believe you meant SAE's.

[Mrgreenfinger]

Cabel with the smack down! Nice job.

[zandant]

Nice. Keep up the good work. With you around refuting all the misstatements and clouded beliefs, we can probably do away with the ignore feature.

[sox040713]

Well done, cabel! I consider P Phase 2a as a proof-of-concept trial. IPIX got what they were hoping for, signs of efficacy at 200 mg.

Don't forget it was the P data that brought Dr. B on board. He was the VP Of Dermatology at Novartis and Senior Director of Dermatology at Pfizer.

[WILD_4_IPIX]

EXCELLENT! Thanks Cabel !

GO IPIX !

[LilyGDog]

Cabel, thanks for your great rebuttal. Go Leo & IPIX!

I think you miss his point!

!) We know we had at least a one point reduction in the degree of psoriasis in 55% of the patients in the 27 patients of the 200mg arm.

2) We know that the drug is dose dependent, the higher the dose the more effective it is.

3) We know what we know from the pre-clinical mouse studies which were spectacular.

4) We know it is very unlikely to have ASE at the higher dosing levels of 300-400mg

5) We know that the drug starts having a positive affect on psoriasis at week 2 with 200mg

6) We know it is easier to get better results with Mod/Sev than Mild/Mod.

7) We know our MODERATE patients responded better than our MILD.

8) We know that an IGA score of 0 or 1 is equivalent to PASI90.

9) We know that the patient satisfaction in the 200mg was high.

10) We know Dr Menon has not failed one trial in at least 5 years.

11) We know Leo has opened many new sites and that he has access to patients results (without knowing what arm they are in)

And against all that the only thing that you have to say is,...

Quote:
Yes but the patient pool was small.


I agree with that,.. and that is why we now dosing are 189 patients in just two dose levels in current Phase 2b. Almost everyone here knows that. But at the same time we know other things about the Phase 2b,.. many of which point to a probable positive outcome.

We tend to look at other things as well as the fact that we had a PoC type trial in Phase 2a (so as to find the right dose),..whereas you look at one thing,... which sets you apart as being very frustrating to discuss anything with.

The ability to see both sides of an argument is the sign of a mature adult,.. try it some time.

If we did a 200 patient trial on B-UP with 200mg dose with foam,.. I would see lots of positives that would indicate it would work and I would put it all together and feel very good about the possibilities.

Plus I would see that the first trial was with just 15 patients and it was small. But that would not take away all the positive things I would see about the samll trial.

We are not saying Phase 2b Prurisol is a 100% lock,... we are saying things are pointing in that direction.

You are saying there is no way to know.

You see one thing and one thing only!

What would you do if you ever served on a Jury and there was ONLY CIRCUMSTANTIAL evidence...?

[JUST 10-11-12]

All true. Go IPIX

[To infinity and beyond!]

much of what you write has no bearing on my point, but if others want to call it a smack down, then it is so, certainly, in the sense of a championship wrestling smack down.

Dose response means what it says. Is it that hard of a concept? IPIX has given up on small doses-50 and 100mg they did not show benefit. They showed some signs of efficacy, as modest as would allow them to continue on with p2b once again, for the record, ITT 7 of 29 vs 4 of 30 placebo, if I recall. That is to say a patient or two here of difference only. there is barely a response at 200 mg if at all. No real response at other doses. So, no dose response.

The other stuff is all well and good, the litany of points, but that was not my concern